- Home
- IKNA vs VNRX Comparison
IKNA vs VNRX Comparison
Compare IKNA & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- VNRX
- Stock Information
- Founded
- IKNA 2016
- VNRX N/A
- Country
- IKNA United States
- VNRX United States
- Employees
- IKNA N/A
- VNRX N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IKNA Health Care
- VNRX Health Care
- Exchange
- IKNA Nasdaq
- VNRX Nasdaq
- Market Cap
- IKNA 61.8M
- VNRX 45.2M
- IPO Year
- IKNA 2021
- VNRX N/A
- Fundamental
- Price
- IKNA $1.08
- VNRX $0.52
- Analyst Decision
- IKNA Buy
- VNRX Strong Buy
- Analyst Count
- IKNA 2
- VNRX 5
- Target Price
- IKNA $3.00
- VNRX $3.75
- AVG Volume (30 Days)
- IKNA 95.3K
- VNRX 172.1K
- Earning Date
- IKNA 05-20-2025
- VNRX 05-20-2025
- Dividend Yield
- IKNA N/A
- VNRX N/A
- EPS Growth
- IKNA N/A
- VNRX N/A
- EPS
- IKNA N/A
- VNRX N/A
- Revenue
- IKNA N/A
- VNRX $1,233,511.00
- Revenue This Year
- IKNA N/A
- VNRX $563.72
- Revenue Next Year
- IKNA N/A
- VNRX $160.43
- P/E Ratio
- IKNA N/A
- VNRX N/A
- Revenue Growth
- IKNA N/A
- VNRX 59.10
- 52 Week Low
- IKNA $0.97
- VNRX $0.42
- 52 Week High
- IKNA $1.94
- VNRX $0.90
- Technical
- Relative Strength Index (RSI)
- IKNA 37.62
- VNRX 52.65
- Support Level
- IKNA $1.22
- VNRX $0.46
- Resistance Level
- IKNA $1.29
- VNRX $0.54
- Average True Range (ATR)
- IKNA 0.09
- VNRX 0.04
- MACD
- IKNA -0.01
- VNRX 0.01
- Stochastic Oscillator
- IKNA 1.75
- VNRX 67.50
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.